首页 > 市场调查报告书 > 医疗设备

手术用器具

市场调查报告书

商品编码

1696270

日本心臟手术器械市场 - 2025 至 2033 年

Japan Cardiac Surgery Instruments Market - 2025-2033

出版日期: 2025年03月25日 | 出版商:

DataM Intelligence | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024 年日本心臟手术器械市场规模达到 8,268 万美元，预计到 2033 年将达到 1.6665 亿美元，在 2025-2033 年预测期内的复合年增长率为 8.1%。

心臟手术器械是高度专业化的工具，旨在协助心胸外科医师对心臟和主要血管进行复杂的手术。这些仪器对于确保手术过程中的精确度、控制力和安全性至关重要，因为它们有助于操纵精细的组织、进行精确的切口和固定缝合。由于心臟手术通常需要对动脉、瓣膜和腔体等结构进行细緻处理，这些器械在提高手术效率和减少併发症方面发挥着至关重要的作用。

这些工具用于各种关键手术，包括冠状动脉绕道手术 (CABG)、心臟瓣膜修復或置换、心臟移植和先天性心臟缺陷矫正。每种手术都需要根据手术的复杂程度来客製化特定的器械，例如血管钳、牵开器、镊子和持针器。心臟手术器械（包括机器人辅助和微创工具）的不断进步，透过缩短恢復时间并降低术后风险进一步改善了患者的治疗效果。

市场动态：

驱动因素与约束因素

心血管疾病发生率上升

日本心血管疾病（CVD）发生率的不断上升是推动心臟手术器械需求的主要因素。日本是世界上人口老化程度最高的国家之一，超过28%的居民年龄在65岁以上，这使他们更容易患上冠状动脉疾病 (CAD)、心臟衰竭和瓣膜疾病等心臟疾病。

根据2024年发布的研究报告，日本心臟衰竭发生率不断上升，预计2030年将达到130万例，将大大推动日本心臟手术器械市场的发展。随着心臟衰竭变得越来越普遍，对心臟手术的需求也随之增加，包括冠状动脉绕道手术 (CABG)、心臟瓣膜修復/置换和其他心臟手术。这直接影响到用于治疗心臟衰竭患者和改善其生活品质的专门手术器械的需求。

由于生活方式因素导致的心血管疾病负担不断增加，再加上诊断和治疗的改善，大大推动了日本对心臟手术器械的需求。随着越来越多的患者接受外科手术和微创手术，医院和外科中心正在投资尖端工具，这进一步推动了市场的成长。

先进手术器械价格昂贵

先进手术器械价格昂贵是日本心臟手术器械市场发展的一大限制因素。对于机器人辅助系统和微创设备等技术来说尤其如此，这些技术可以提供更高的精度和更快的恢復时间，但价格也相当昂贵。这些先进技术所需的初始投资可能非常昂贵，特别是对于预算有限的小型医院或医疗中心而言。在某些地区，高昂的前期成本使得医院难以广泛采用这些尖端工具。

对日本6家医院实施的经皮腔内冠状动脉成形术（PTCA）的成本分析显示，每次手术的人工成本在65,000日元至98,000日元之间。这凸显了心臟介入治疗所需的大量资金投入。此外，每次手术一次性材料的费用从 1,000 日元到 39,000 日元不等，包括劳动力、材料和资本投资在内的总成本在 95,000 日元到 224,000 日元之间。这些成本的差异反映了地区预算限制和医院之间的不同财务优先顺序如何影响其投资先进技术的能力，从而限制其采用和融入临床实践。

市场领导者和先驱者
- 新兴先锋和杰出参与者
- 拥有销售量最大的品牌的既定领导者
- 拥有成熟产品的市场领导者
CXO 观点
最新进展与突破
案例研究/正在进行的研究
监管和报销情况
波特五力分析
供应链分析
专利分析
SWOT 分析
未满足的需求和差距
市场进入和扩张的推荐策略
情境分析：最佳情况、基本情况和最坏情况预测
定价分析和价格动态
关键意见领袖

第 5 章：日本心臟手术器械市场（依产品类型）

手术器械
- 钳子
- 夹具
- 手术刀
- 剪刀
- 持针器
- 其他的
心臟监测仪器
冠状动脉绕道手术 (CABG) 器械
心臟瓣膜修復和置换器械
内视镜和机器人器械
心肺旁路设备
其他的

第 6 章：日本心臟手术器械市场（依应用）

冠状动脉绕道手术
心臟瓣膜手术
小儿外科
心臟移植
其他的

第 7 章：日本心臟手术器械市场（依最终用户划分）

医院和心臟中心
门诊手术中心
其他的

第 8 章：竞争格局与市场定位

竞争概况和主要市场参与者
市占率分析与定位矩阵
策略伙伴关係、併购
产品组合和创新的关键发展
公司基准化分析

第九章：公司简介

Medtronic

公司概况
产品组合
- 产品描述
- 产品关键绩效指标 (KPI)
- 历史和预测产品销售量
- 产品销售量
财务概览
- 公司收入
- 地区收入份额
- 收入预测
关键进展
- 合併与收购
- 关键产品开发活动
- 监管部门批准等
SWOT 分析

Johnson & Johnson (Ethicon)
Abbott.
Siemens Healthineers
GE Healthcare
Boston Scientific Corporation
Terumo Cardiovascular Systems Corporation.
Stryker
Koninklijke Philips NV
Edwards Lifesciences Corporation.

第 10 章：假设与研究方法

资料收集方法
数据三角测量
预测技术
数据验证和确认

第 11 章：附录

简介目录

Product Code: MD9377

The Japan cardiac surgery instruments market reached US$ 82.68 million in 2024 and is expected to reach US$ 166.65 million by 2033, growing at a CAGR of 8.1 % during the forecast period 2025-2033.

Cardiac surgery instruments are highly specialized tools designed to assist cardiothoracic surgeons in performing complex procedures on the heart and major blood vessels. These instruments are essential for ensuring precision, control, and safety during surgery, as they help manipulate delicate tissues, make accurate incisions, and secure sutures. Since heart surgeries often require meticulous handling of structures like arteries, valves, and chambers, these instruments play a crucial role in improving surgical efficiency and reducing complications.

These tools are used in a variety of critical procedures, including coronary artery bypass grafting (CABG), heart valve repair or replacement, heart transplants, and congenital heart defect corrections. Each of these surgeries demands specific instruments tailored to the procedure's complexity, such as vascular clamps, retractors, forceps, and needle holders. The continuous advancement of cardiac surgery instruments, including robotic-assisted and minimally invasive tools, has further enhanced patient outcomes by reducing recovery times and minimizing post-operative risks.

Market Dynamics: Drivers & Restraints

Rising Incidence of Cardiovascular Diseases

The increasing prevalence of cardiovascular diseases (CVDs) in Japan is a major factor driving demand for cardiac surgery instruments. Japan has one of the world's oldest populations, with over 28% of its residents aged 65 and older, making them more susceptible to heart diseases such as coronary artery disease (CAD), heart failure, and valve disorders.

According to the research study published in 2024, the rising prevalence of heart failure in Japan, projected to reach 1.3 million cases by 2030, is significantly driving the Japan cardiac surgery instruments market. As heart failure becomes more common, the demand for cardiac surgeries including coronary artery bypass grafting (CABG), heart valve repairs/replacements, and other heart surgeries increases. This directly impacts the need for specialized surgical instruments designed to treat heart failure patients and improve their quality of life.

The increasing burden of CVDs due to lifestyle factors, coupled with improvements in diagnosis and treatment, is significantly driving the demand for cardiac surgery instruments in Japan. As more patients undergo surgical and minimally invasive procedures, hospitals and surgical centers are investing in cutting-edge tools, which is further boosting the growth of the market.

High Cost of Advanced Surgical Instruments

The high cost of advanced surgical instruments is a major constraint in the Japanese cardiac surgery instruments market. This is particularly true for technologies like robotic-assisted systems and minimally invasive devices, which offer improved precision and faster recovery times but come with a significant price tag. The initial investment required for these advanced technologies can be prohibitively expensive, especially for smaller hospitals or healthcare centers that are already working with limited budgets. In certain regions, the high upfront costs make it challenging for hospitals to widely adopt these cutting-edge tools.

A cost analysis of percutaneous transluminal coronary angioplasty (PTCA) performed at six Japanese hospitals showed that labor costs ranged from yen 65,000 to yen 98,000 per procedure. This highlights the significant financial commitment required for cardiac interventions. In addition, the costs for disposable materials varied from yen 1,000 to yen 39,000 per procedure, bringing the total cost including labor, materials, and capital investment to between yen 95,000 and yen 224,000. The variation in these costs reflects how regional budget constraints and differing financial priorities among hospitals can impact their ability to invest in advanced technologies, limiting their adoption and integration into clinical practices.

Segment Analysis

The Japan cardiac surgery instruments market is segmented based on product type, application, and end-user.

Product Type:

The coronary artery bypass grafting (CABG) segment in the product type is expected to dominate Japan cardiac surgery instruments market share

The coronary artery bypass grafting (CABG) segment is a critical component of the Japan cardiac surgery instruments market, driven by the high prevalence of coronary artery disease (CAD) in the country. CABG is one of the most common cardiac surgical procedures, used to treat severe cases of CAD where coronary arteries become narrowed or blocked, restricting blood flow to the heart muscle. This procedure is typically required when other treatments, such as medication or angioplasty, are not sufficient to restore normal blood flow.

Furthermore, key players in the industry product launches drive this segment's growth in the Japan cardiac surgery instruments market. For instance, in August 2024, DePuy Synthes, the orthopedics division of Johnson & Johnson and part of Johnson & Johnson MedTech, launched the MatrixSTERNUM Fixation System. This plate and screw fixation system is specifically designed to stabilize and secure the front part of the chest wall after surgeries like open-heart surgery and thoracic surgery. The MatrixSTERNUM system addresses a critical need in the cardiac and thoracic surgery market by offering a more efficient and effective solution for post-surgical stabilization.

The introduction of advanced systems like the MatrixSTERNUM Fixation System is driving innovation in the Japan cardiac surgery instruments market. As Japan experiences an increasing number of cardiac and thoracic surgeries, hospitals are seeking more efficient, reliable, and patient-friendly solutions for surgical stabilization. These factors have solidified the segment's position in the Japan cardiac surgery instruments market.

Competitive Landscape

The major players in the Japan cardiac surgery instruments market include Medtronic, Johnson & Johnson (Ethicon), Abbott., Siemens Healthineers, GE Healthcare, Boston Scientific Corporation, Terumo Cardiovascular Systems Corporation., Stryker, Koninklijke Philips N.V., and Edwards Lifesciences Corporation among others.

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Japan cardiac surgery instruments market report delivers a detailed analysis with 40+ key tables, more than 30 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Market Introduction and Scope

1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope

2. Executive Insights and Key Takeaways

2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Product Type
2.4. Snippet by Application
2.5. Snippet by End-User

3. Dynamics

3.1. Impacting Factors
- 3.1.1. Drivers
  - 3.1.1.1. Rising Incidence of Cardiovascular Diseases
  - 3.1.1.2. Technological Advancements in Cardiac Surgery
- 3.1.2. Restraints
  - 3.1.2.1. High Cost of Advanced Surgical Instruments
  - 3.1.2.2. Stringent Regulatory Requirements
- 3.1.3. Opportunity
  - 3.1.3.1. Rising Demand for Minimally Invasive Surgery
- 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

4.1. Market Leaders and Pioneers
- 4.1.1. Emerging Pioneers and Prominent Players
- 4.1.2. Established leaders with the largest-selling Brand
- 4.1.3. Market leaders with established Product
4.2. CXO Perspectives
4.3. Latest Developments and Breakthroughs
4.4. Case Studies/Ongoing Research
4.5. Regulatory and Reimbursement Landscape
4.6. Porter's Five Forces Analysis
4.7. Supply Chain Analysis
4.8. Patent Analysis
4.9. SWOT Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
4.14. Key Opinion Leaders

5. Japan Cardiac Surgery Instruments Market, By Product Type

5.1. Introduction
- 5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 5.1.2. Market Attractiveness Index, By Product Type
5.2. Surgical Instruments*
- 5.2.1. Introduction
- 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 5.2.3. Forceps
- 5.2.4. Clamps
- 5.2.5. Scalpels
- 5.2.6. Scissors
- 5.2.7. Needle Holders
- 5.2.8. Others
5.3. Cardiac Monitoring Instruments
5.4. Coronary Artery Bypass Grafting (CABG) Instruments
5.5. Heart Valve Repair & Replacement Instruments
5.6. Endoscopic and Robotic Instruments
5.7. Cardiopulmonary Bypass Equipment
5.8. Others

6. Japan Cardiac Surgery Instruments Market, By Application

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 6.1.2. Market Attractiveness Index, By Application
6.2. Coronary Artery Bypass Grafting*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Heart Valve Surgery
6.4. Pediatric Surgery
6.5. Heart Transplant
6.6. Others

7. Japan Cardiac Surgery Instruments Market, By End-User

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 7.1.2. Market Attractiveness Index, By End-User
7.2. Hospitals and Cardiac Centers*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Ambulatory Surgery Centers
7.4. Others

8. Competitive Landscape and Market Positioning

8.1. Competitive Overview and Key Market Players
8.2. Market Share Analysis and Positioning Matrix
8.3. Strategic Partnerships, Mergers & Acquisitions
8.4. Key Developments in Product Portfolios and Innovations
8.5. Company Benchmarking

9. Company Profiles

9.1. Medtronic *
- 9.1.1. Company Overview
- 9.1.2. Product Portfolio
  - 9.1.2.1. Product Description
  - 9.1.2.2. Product Key Performance Indicators (KPIs)
  - 9.1.2.3. Historic and Forecasted Product Sales
  - 9.1.2.4. Product Sales Volume
- 9.1.3. Financial Overview
  - 9.1.3.1. Company Revenue's
  - 9.1.3.2. Geographical Revenue Shares
  - 9.1.3.3. Revenue Forecasts
- 9.1.4. Key Developments
  - 9.1.4.1. Mergers & Acquisitions
  - 9.1.4.2. Key Product Development Activities
  - 9.1.4.3. Regulatory Approvals, etc.
- 9.1.5. SWOT Analysis
9.2. Johnson & Johnson (Ethicon)
9.3. Abbott.
9.4. Siemens Healthineers
9.5. GE Healthcare
9.6. Boston Scientific Corporation
9.7. Terumo Cardiovascular Systems Corporation.
9.8. Stryker
9.9. Koninklijke Philips N.V.
9.10. Edwards Lifesciences Corporation.